A detailed history of Commonwealth Equity Services, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 15,276 shares of NBIX stock, worth $1.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,276
Previous 14,916 2.41%
Holding current value
$1.92 Million
Previous $2.05 Million 14.31%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$114.58 - $153.15 $41,248 - $55,134
360 Added 2.41%
15,276 $1.76 Million
Q2 2024

Jul 31, 2024

BUY
$130.86 - $143.19 $127,588 - $139,610
975 Added 6.99%
14,916 $2.05 Million
Q1 2024

Apr 29, 2024

BUY
$130.4 - $143.74 $10,953 - $12,074
84 Added 0.61%
13,941 $1.92 Million
Q4 2023

Feb 06, 2024

SELL
$106.07 - $132.76 $15,910 - $19,914
-150 Reduced 1.07%
13,857 $1.83 Million
Q3 2023

Oct 23, 2023

SELL
$94.02 - $117.1 $103,139 - $128,458
-1,097 Reduced 7.26%
14,007 $1.58 Million
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $20,950 - $24,539
-234 Reduced 1.53%
15,104 $1.42 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $18,822 - $24,604
200 Added 1.32%
15,338 $1.55 Million
Q4 2022

Feb 07, 2023

BUY
$106.72 - $127.06 $46,956 - $55,906
440 Added 2.99%
15,138 $1.81 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $166,482 - $195,028
-1,809 Reduced 10.96%
14,698 $1.56 Million
Q2 2022

Jul 19, 2022

SELL
$75.79 - $100.07 $162,039 - $213,949
-2,138 Reduced 11.47%
16,507 $1.61 Million
Q1 2022

May 04, 2022

BUY
$72.45 - $94.81 $13,185 - $17,255
182 Added 0.99%
18,645 $1.75 Million
Q4 2021

Jan 31, 2022

SELL
$79.65 - $106.22 $27,240 - $36,327
-342 Reduced 1.82%
18,463 $1.57 Million
Q3 2021

Oct 29, 2021

SELL
$86.18 - $99.03 $118,497 - $136,166
-1,375 Reduced 6.81%
18,805 $1.8 Million
Q2 2021

Aug 11, 2021

BUY
$89.43 - $102.27 $48,023 - $54,918
537 Added 2.73%
20,180 $1.96 Million
Q1 2021

May 04, 2021

SELL
$87.57 - $119.4 $106,922 - $145,787
-1,221 Reduced 5.85%
19,643 $1.91 Million
Q4 2020

Feb 11, 2021

SELL
$86.91 - $108.33 $284,890 - $355,105
-3,278 Reduced 13.58%
20,864 $2 Million
Q3 2020

Nov 05, 2020

BUY
$96.16 - $135.15 $20,866 - $29,327
217 Added 0.91%
24,142 $2.32 Million
Q2 2020

Aug 12, 2020

BUY
$85.09 - $130.36 $59,988 - $91,903
705 Added 3.04%
23,925 $2.92 Million
Q1 2020

May 11, 2020

BUY
$75.11 - $113.76 $19,904 - $30,146
265 Added 1.15%
23,220 $2.01 Million
Q4 2019

Feb 05, 2020

BUY
$86.8 - $118.57 $756,982 - $1.03 Million
8,721 Added 61.27%
22,955 $2.47 Million
Q3 2019

Oct 30, 2019

SELL
$83.82 - $101.5 $19,446 - $23,548
-232 Reduced 1.6%
14,234 $1.28 Million
Q2 2019

Jul 19, 2019

SELL
$72.24 - $91.27 $41,610 - $52,571
-576 Reduced 3.83%
14,466 $1.22 Million
Q1 2019

May 13, 2019

BUY
$69.31 - $91.53 $323,331 - $426,987
4,665 Added 44.96%
15,042 $1.33 Million
Q4 2018

Feb 11, 2019

SELL
$68.32 - $124.36 $46,525 - $84,689
-681 Reduced 6.16%
10,377 $741,000
Q3 2018

Nov 06, 2018

BUY
$98.88 - $125.85 $888,832 - $1.13 Million
8,989 Added 434.46%
11,058 $1.36 Million
Q2 2018

Jul 31, 2018

BUY
$75.3 - $105.99 $155,795 - $219,293
2,069 New
2,069 $203,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.